2 results
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
Approved WMORecruiting
Main study:Primary:Efficacy:- To assess the clinical outcome at 30 days follow-up after administration of a single subcutaneous injection of zalunfiban versusplacebo in STEMI subjects in the pre-hospital setting.Safety:- To assess bleeding events (…